Table 1 Characteristics of the subjects
From: Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort
All patients (n = 824) | |
|---|---|
Age (years, mean (SD)) | 58.9 (13.7) |
Male, n (%) | 401 (48.7) |
BMI (kg/m2, mean (SD)) | 24.3 (3.0) |
Medical history | |
Dyslipidemia, n/N (%) | 128/822 (15.6) |
Hypertension, n/N (%) | 278/822 (33.8) |
Diabetes, n/N (%) | 147/822 (17.9) |
Chronic kidney disease, n/N (%) | 166/822 (20.2) |
HIV Infection, n/N (%) | 5/822 (0.6) |
Chronic liver disease, n/N (%) | 552/822 (67.2) |
Cardiovascular disease, n/N (%) | 17/818 (2.1) |
Cerebrovascular disease, n/N (%) | 10/818 (1.2) |
COPD, n/N (%) | 14/818 (1.7) |
History of malignancy, n/N (%) | 101/822 (12.3) |
Charlson comorbidity index (mean (SD)) | 2.0 (1.8) |
Charlson Comorbidity index (median (range)) | 1 (0–13) |
Charlson comorbidity index | 5.44 (0.98) |
0 | 130 (15.8) |
1 | 305 (37.0) |
2 | 146 (17.7) |
3 | 112 (13.6) |
4 | 46 (5.6) |
5 | 36 (4.4) |
≧ 6 | 49 (5.9) |
SARS-CoV-2 IgG (AU/mL, median (range)) | 9812 (87–236,599) |
SARS-CoV-2 IgG (log BAU/mL, mean (SD)) | 3.11 (0.46) |
Time of blood testing after the 3rd vaccination (days, mean (SD)) | 49.1 (20.4) |